173 related articles for article (PubMed ID: 37642143)
1. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
[TBL] [Abstract][Full Text] [Related]
2. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer.
Kurokawa K; Mitsuishi Y; Shimada N; Ito N; Ogiwara M; Miura K; Asao T; Ko R; Shukuya T; Shibayama R; Goto H; Takahashi K
Thorac Cancer; 2023 Feb; 14(5):442-449. PubMed ID: 36523162
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer.
Ida H; Goto Y; Sato J; Kanda S; Shinno Y; Morita R; Murakami S; Matsumoto Y; Yoshida T; Horinouchi H; Fujiwara Y; Yamamoto N; Fukuda T; Ohashi K; Ohe Y
Med Oncol; 2020 Mar; 37(4):30. PubMed ID: 32180046
[TBL] [Abstract][Full Text] [Related]
6. Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia.
Baldawi MB; Dhami B; Gosai J; Al-Khafaji RH
Cureus; 2022 Aug; 14(8):e28393. PubMed ID: 36171843
[TBL] [Abstract][Full Text] [Related]
7. A Case of Cancer-Associated Hyponatraemia: Primary Adrenal Insufficiency Secondary to Nivolumab.
Galliazzo S; Morando F; Sartorato P; Bortolin M; De Menis E
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):363-366. PubMed ID: 34238203
[TBL] [Abstract][Full Text] [Related]
8. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
9. Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
Paepegaey AC; Lheure C; Ratour C; Lethielleux G; Clerc J; Bertherat J; Kramkimel N; Groussin L
J Endocr Soc; 2017 Jun; 1(6):646-649. PubMed ID: 29264517
[TBL] [Abstract][Full Text] [Related]
10. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
11. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A
J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
13. Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer.
Kagoshima H; Hori R; Kojima T; Okanoue Y; Fujimura S; Taguchi A; Shoji K
Auris Nasus Larynx; 2020 Apr; 47(2):309-313. PubMed ID: 31235078
[TBL] [Abstract][Full Text] [Related]
14. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH
Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370
[TBL] [Abstract][Full Text] [Related]
16. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
17. Severe oral ulcerative and lichenoid lesions associated with adrenal insufficiency in a patient treated with nivolumab: Report of a case and review of literature.
Gobbi MF; Eduardo FP; Bezinelli LM; de Carvalho DLC; Monção do Vale SK; Corrêa L
Spec Care Dentist; 2022 May; 42(3):286-293. PubMed ID: 34717001
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Blanchard A; Bouchard N
Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
[TBL] [Abstract][Full Text] [Related]
19. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
20. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]